Answers to Everyday Practice Challenges in HIV Medicine
A Phone-a-Friend CME Series – Volume 2
Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) From dolutegravir (DTG)+F/TAF or DTG+F/tenofovir disoproxil fumarate (TDF) in the presence of pre-existing NRTI resistance.
Acosta RK, Willkom M, Andreatta K, et al. J Acquir Immune Defic Syndr. 2020;85(3):363-371.
Cognitive impairment in people living with HIV in the ART era: A Review.
Alford K, Vera JH. British Medical Bulletin. 2018;127(1):55-68.
Provision of onsite HIV Services in Substance Use Disorder Treatment Programs: A longitudinal analysis.
Aletaris L, Roman PM. J Subst Abuse Treat. 2015;57:1-8.
Weight and metabolic changes after switching from tenofovir alafenamide (TAF)/emtricitabine (FTC) +dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, and TDF/FTC/efavirenz (EFV) to TDF/lamivudine (3TC)/DTG.
Bosch B, Akpomiemie G, Chandiwana N, et al. Clin Infect Dis. 2022; ciac949.
First demonstration project of long-acting injectable antiretroviral therapy for persons with and without detectable human immunodeficiency virus (HIV) viremia in an urban HIV clinic.
Christopoulos KA, Grochowski J, Mayorga-Munoz F, et al. Clin Infect Dis. 2022; ciac631.
Factors associated with resilience among Black women living with HIV and histories of trauma.
Dale SK, Reid R, Safren SA. J Health Psychol. 2021;26(5):758-766.
The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals.
Ehrenkranz P, Rosen S, Boule A, et al. PLoS Med. 2021;18(5):e1003651.
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.
Eggers C, Arendt G, Hahn K, et al. J Neurol. 2017;264(8):1715-1727.
Phase 3 study of ibalizumab for multidrug-resistant HIV-1.
Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.
The conundrum of 'long-COVID-19': a narrative review.
Garg M, Maralakunte M, Garg S, et al. Int J Gen Med. 2021;14:2491-2506.
Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
Gupta SK, Berhe M, Crofoot G, et al. Lancet HIV. 2023;10(1):e15-e23.
Switching to bictegravir/emtrictabine/tenofovir alafenamide in Black americans with HIV-1: a randomized phase 3b, multicenter, open-label study.
Hagins D, Kumar P, Saag M, et al. J Acquir Immune Defic Syndr. 2021;88(1):86-85.
Gender and sexual identity in adolescence: A mixed-methods study of labeling in diverse community settings.
Hammack PL, Hughes SD, Atwood JM, et al. J Adolesc Res. 2021;37(2):167-220.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.
Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.
Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap.
McArthur JC, Steiner J, Sacktor N, et al. Ann Neurol. 2010;67(6):699-714.
Beyond Core Indicators of Retention in HIV Care: Missed Clinic Visits Are Independently Associated with All-Cause Mortality.
Mugavero MJ, Westfall AO, Cole SR, et al. Clin Infect Dis. 2014;59(10):1471-1479.
Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.
Neesgaard B, Greenberg L, Miró JM, et al. Lancet HIV. 2022;9(7):e474-e485.
Changes in weight and BMI with first-line doravirine-based therapy.
Orkin C, Elion R, Thompson M, et al. AIDS. 2021;35(1):91-99.
Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV.
Paton NI, Musaazi J, Kityo C, et al. N Engl J Med. 2021;385(4):330-341.
Post-acute sequelae and adaptive immune responses in people living with HIV recovering from SARS-CoV-2 infection.
Peluso MJ, Spinelli MA, Deveau T-M, et al. AIDS. 2022;36(12):F7-F16.
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): Final results of a multicentre, prospective, observational study.
Rodger AJ, Cambiano V, Bruun T, et al. Lancet. 2019;393(10189):2428-2438.
Aging, comorbidities, and the importance of finding biomarkers for HIV-associated neurocognitive disorders.
Rosenthal J, Tyor W. J Neurovirol. 2019;25(5):673-685.
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials.
Sax PE, Erlandson KM, Lake JE, et al. Clin Infect Dis. 2020;71(6):1380-1390.
Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.
Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.
Ethnic inequalities in mental health and socioeconomic status among older women living with HIV: result from the PRIME Study.
Solomon D, Tariq S, Alldis J, et al. Sex Transm Infect. 2022;98(2):128-131.
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
Sordo L, Barrio G, Bravo MJ, et al. BMJ 2017;357:j1550.
Nirmatrelvir and the risk of post-acute sequelae of COVID-19.
Xie Y, Choi T, Al-Aly Z. medRxiv. 2022:11.03.22281783.
Clinical Practice Guidelines
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services
Long COVID or post-COVID conditions.
Centers for Disease Control and Prevention (CDC).
Characteristics, prevention, and management of cardiovascular disease in people living with HIV: A scientific statement from the American Heart Association.
Feinstein MJ, Hsue PY, Benjamin LA, et al. Circulation. 2019;140(2):e98-e124.
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, Stone NJ, Bailey AL, et al. Circulation. 2019;139(25):e1046-e1081.
Clinician Resources
ASCVD Risk Estimator Plus.
American College of Cardiology.
Ward 86 long-acting injectable antiretroviral protocol.
Getting to Zero San Francisco.
HIV Drug Resistance Database
Stanford University.
HIV drug interactions.
University of Liverpool.
Medications for Substance Use Disorder
Substance Abuse and Mental Health Services Administration (SAMHSA)
Patient and Caregiver Resources
AIDSMap Resources
NAM Publications
Resources for persons living with HIV
Centers for Disease Control and Prevention
HIV resources
National Institutes of Health
Mental Health in Aging People With HIV: Module 1
A Phone-a-Friend Peer Consult Series
| Faculty: | Richard A. Elion, MD; Glenn Jordan Treisman, MD, PhD |
| Release: | 12/12/2022 |
| Expiration: | 12/12/2023 |
Long COVID in Patients with HIV: Module 2
A Phone-a-Friend Peer Consult Series
| Faculty: | Onyema Ogbuagu, MBBCh, FACP, FIDSA; Michael Peluso, MD, MPhil, MHS, DTM&H |
| Release: | 02/02/2023 |
| Expiration: | 02/02/2024 |
Salvage Regimens for HTE Patients: Module 3
A Phone-a-Friend Peer Consult Series
| Faculty: | Onyema Ogbuagu, MBBCh, FACP, FIDSA; José R. Arribas, MD |
| Release: | 02/09/2023 |
| Expiration: | 02/09/2024 |
Long-Acting Injectable Implementation: Module 4
A Phone-a-Friend Peer Consult Series
| Faculty: | Richard A. Elion, MD; Monica Gandhi, MD, MPH |
| Release: | 02/16/2023 |
| Expiration: | 02/16/2024 |
Virologic Failure in HIV: Module 5
A Phone-a-Friend Peer Consult Series
| Faculty: | Anna Maria Geretti, MD, PhD, FRCPath; Laura Waters, MD, FRCP |
| Release: | 02/23/2023 |
| Expiration: | 02/23/2024 |
Challenges in Social Determinants of Health: Module 6
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Fiona Burns, PhD, FRCP; Laura Waters, MD, FRCP |
| Release: | 03/02/2023 |
| Expiration: | 03/02/2024 |
Persistent Challenges in HIV in People Who Inject Drugs: Module 7
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Frederick Altice, MD; Onyema Ogbuagu, MBBCh, FACP, FIDSA |
| Release: | 03/09/2023 |
| Expiration: | 03/09/2024 |
Management of People With HIV Coinfected With Hepatitis B and Hepatitis D Viruses: Module 8
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Jürgen Rockstroh, MD; Laura Waters, MD, FRCP |
| Release: | 03/16/2023 |
| Expiration: | 03/16/2024 |
Management of People with HIV and Weight Gain: Module 9
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Paul E. Sax, MD; Laura Waters, MD, FRCP |
| Release: | 03/23/2023 |
| Expiration: | 03/23/2024 |
Recognizing and Addressing Health Disparities Among Black Women: Module 10
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Onyema Ogbuagu, MBBCH, FACP, FIDSA; Aimalohi Ahonkhai, MD, MPH |
| Release: | 03/30/2023 |
| Expiration: | 03/30/2024 |
Adolescents and Young Adults with HIV: Module 11
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Richard A. Elion, MD; Renata Sanders, MD, MPH, ScM |
| Release: | 04/06/2023 |
| Expiration: | 04/06/2024 |
Examining CVD in People with HIV: Module 12
A Phone-a-Friend Peer Consult Series—Volume 2
| Faculty: | Richard A. Elion, MD; Priscilla Hsue, MD |
| Release: | 04/13/2023 |
| Expiration: | 04/13/2024 |
